Roivant Going Public Via MAAC SPAC Merger for ~$7.3B
Shots:
- Roivant signs a SPAC merger with MAAC for ~7.3B including $411M in cash in the MAAC trust account and $200M in PIPE stock at $10.00/share. The transaction is expected to deliver ~$611M to fund discovery and development programs and is expected to close in Q3’21
- Roivant equity holders and Patient Square Capital have agreed to lock up at least half shares for ~3yrs. Pro forma net cash position of ~$2.3B following transaction will enable strategic pipeline expansion through internal drug discovery and in-licensing- continued development and commercialization
- The current shareholders of Roivant will own ~ 92% of the combined company while Roivant expect to trade on Nasdaq under the ticker "ROIV’’
Ref: PRNewswire | Image: MAAC
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com